The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
The price of Theriva Biologics Inc (AMEX: TOVX) closed at $0.31 in the last session, down -3.58% from day before closing price of $0.32. In other words, the price has decreased by -$3.58 from its previous closing price. On the day, 3.4 million shares were traded. TOVX stock price reached its highest trading level at $0.3199 during the session, while it also had its lowest trading level at $0.3003.
Ratios:
We take a closer look at TOVX’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 1.19 and its Current Ratio is at 1.19. In the meantime, Its Debt-to-Equity ratio is 0.27 whereas as Long-Term Debt/Eq ratio is at 0.21.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TOVX now has a Market Capitalization of 7314417 and an Enterprise Value of -6230600.
Stock Price History:
The Beta on a monthly basis for TOVX is 0.55, which has changed by -0.85024154 over the last 52 weeks, in comparison to a change of 0.19736934 over the same period for the S&P500. Over the past 52 weeks, TOVX has reached a high of $2.64, while it has fallen to a 52-week low of $0.28. The 50-Day Moving Average of the stock is -23.34%, while the 200-Day Moving Average is calculated to be -60.15%.
Shares Statistics:
According to the various share statistics, TOVX traded on average about 14.14M shares per day over the past 3-months and 62994230 shares per day over the past 10 days. Insiders hold about 1.04% of the company’s shares, while institutions hold 1.24% stake in the company. Shares short for TOVX as of 1760486400 were 387988 with a Short Ratio of 0.03, compared to 1757894400 on 331552. Therefore, it implies a Short% of Shares Outstanding of 387988 and a Short% of Float of 4.05.
Earnings Estimates
The market rating of Theriva Biologics Inc (TOVX) is currently shaped by the ongoing analysis conducted by 1.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.37, with high estimates of -$0.37 and low estimates of -$0.37.
Analysts are recommending an EPS of between -$2.15 and -$2.15 for the fiscal current year, implying an average EPS of -$2.15. EPS for the following year is -$0.75, with 1.0 analysts recommending between -$0.75 and -$0.75.
